Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 10/20 | 0.39 |
| ▸ | FLT1 | P17948 | 2/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 3/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.35 |
| ▸ | ULK1 | O75385 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2598775 | 0.88 | KDR (0.48) | KDRPDGFRBFGFR2FLT3EGFR | |
| SCHEMBL2598501 | 0.83 | EGFR (0.45) | KDRPDGFRBFGFR2FLT3EGFR | |
| SCHEMBL2598701 | 0.81 | KDR (0.42) | KDRPDGFRBFGFR2FLT3EGFR | |
| SCHEMBL2598757 | 0.80 | KDR (0.43) | KDRPDGFRBFGFR2FLT3EGFR | |
| SCHEMBL14839833 | 0.80 | BACE1 (0.33) | EGFR | |
| SCHEMBL2598694 | 0.79 | EGFR (0.43) | KDRPDGFRBFGFR2FLT3EGFR | |
| SCHEMBL2598723 | 0.77 | EGFR (0.44) | KDRPDGFRBFGFR2FLT3EGFR | |
| SCHEMBL12185893 | 0.73 | EGFR (0.52) | EGFRPRKD1SYK | |
| SCHEMBL2598768 | 0.72 | PIK3CA (0.46) | KDRPDGFRBEGFRSYK | |
| SCHEMBL2598577 | 0.71 | SYK (0.46) | KDRFGFR2FLT3EGFRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | claimed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | claimed |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2013-04-11 | — | — | US | claimed |
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | disclosed |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| EP-2571867-A1 | NOVEL PYRIMIDINE DERIVATIVES | Chemilia AB (SE) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011144742-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | KDR 1568/4885PDGFRB 1346/4885FGFR2 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.